1. Home
  2. FRPT vs SRPT Comparison

FRPT vs SRPT Comparison

Compare FRPT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

HOLD

Current Price

$50.00

Market Cap

2.4B

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$16.17

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPT
SRPT
Founded
2004
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
FRPT
SRPT
Price
$50.00
$16.17
Analyst Decision
Buy
Hold
Analyst Count
17
29
Target Price
$76.94
$25.85
AVG Volume (30 Days)
1.9M
2.8M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
183.87
N/A
EPS
0.91
2.88
Revenue
$1,102,015,000.00
$2,198,237,000.00
Revenue This Year
$11.34
N/A
Revenue Next Year
$9.13
N/A
P/E Ratio
$54.79
$5.64
Revenue Growth
13.01
15.58
52 Week Low
$46.45
$10.42
52 Week High
$86.00
$43.92

Technical Indicators

Market Signals
Indicator
FRPT
SRPT
Relative Strength Index (RSI) 38.78 33.89
Support Level $47.59 $15.70
Resistance Level $56.73 $19.62
Average True Range (ATR) 2.26 0.76
MACD 0.52 -0.07
Stochastic Oscillator 51.82 6.77

Price Performance

Historical Comparison
FRPT
SRPT

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: